N4 Pharma a deeper understanding of the capabilities of Nuvec (Interview)

N4 Pharma plc (LON:N4P) CEO Nigel Theobald joins DirectorsTalk Interviews to discuss interim results for the six months ended 30 June 2021. Nigel talks us through the highlights, talks about the increased understanding of the capabilities of Nuvec, progress on the two MTA´s, patents from the European, Australian, and Japanese patent offices and what can investors expect from N4 Pharma in the next 6 months.

N4 Pharma, are a specialist pharmaceutical company developing a novel silica nanoparticle delivery system for vaccines and therapeutics for licensing to pharmaceutical and biotech partners.

You might also enjoy reading  N4 Pharma pleased with initial in vitro results from new SARS-COV-2 plasmid

Share this interview

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on whatsapp
WhatsApp
N4 Pharma a deeper understanding of the capabilities of Nuvec (Interview)

Other Interviews

More News

Ask your questions

Do you have questions you’d like to ask this company, get in touch and we’ll ask them for you.   

I have questions